Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) triggered by pregnancy is a rare disease caused by dysregulation of the alternative complement pathway that occurs in approximately 1 in 25,000 pregnancies. The 311 phase 3 trial (NCT02949128) showed that ravulizumab, a long-acting C5 inhibitor o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gäckler, Anja, Schönermarck, Ulf, Dobronravov, Vladimir, La Manna, Gaetano, Denker, Andrew, Liu, Peng, Vinogradova, Maria, Yoon, Sung-Soo, Praga, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786907/
https://www.ncbi.nlm.nih.gov/pubmed/33407224
http://dx.doi.org/10.1186/s12882-020-02190-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786907/
https://www.ncbi.nlm.nih.gov/pubmed/33407224
http://dx.doi.org/10.1186/s12882-020-02190-0

Ejemplares similares